Abstract
Accurate quantification of protein biomarkers is essential for early diagnosis, effective patient stratification in clinical trials, and efficient clinical research aimed at tackling Alzheimer’s disease (AD). Gold-standard tests including PET scans and CSF analysis often rely on complex, invasive, and costly technologies. A reliable blood-based biomarker test with precise and sensitive quantification capabilities can accelerate breakthroughs, support therapeutic development, and significantly improve outcomes.
Taudia’s SPLASH™ technology and NeuXplore™ platform deliver a new standard of sensitivity and precision in blood-based biomarker testing for Alzheimer’s disease. With fg/mL-level detection and single-digit %CV precision, the technology enables fast, scalable measurement of key biomarkers like pTau217 and Aβ42. By streamlining workflows and enhancing analytical accuracy, NeuXplore™ has the potential to transform early detection strategies and accelerate patient recruitment for Alzheimer’s clinical trials.
Key takeaways
- Accurate protein biomarker quantification is critical for early AD diagnosis, clinical trial stratification, and research — but gold-standard methods are invasive, complex, and expensive.
- A precise, sensitive, and scalable blood-based assay could accelerate therapeutic development and improve clinical outcomes in Alzheimer’s disease.
- Taudia’s SPLASH™ technology and NeuXplore™ instrument set a new benchmark in blood-based biomarker detection, offering fg/mL-level sensitivity and single-digit %CV precision.
Speakers
Paul Hung, PhD. CEO, Taudia
Paul Hung is a serial entrepreneur with a track record of successful commercialization and exits. His companies – CellASIC and Combinati – were acquired by Millipore Sigma and Thermo Fisher Scientific, respectively. At Taudia, Paul draws on his extensive experience to turn cutting-edge science into market-ready products.
Ted Wilson, PhD. Stanford University ADRC
Dr. Edward (Ted) Wilson leads all fluid biomarker testing at Stanford’s Alzheimer’s Disease Research Center (ADRC). His research accelerates the discovery of precision biomarkers and therapeutic pathways, advancing the fight against neurodegenerative diseases.